Profound Medical Says Johns Hopkins Treats First Patient With Tulsa-Pro Prostate Cancer Therapy

MT Newswires Live01-07

Profound Medical (PROF) said Tuesday that Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the company's Tulsa-Pro system.

Tulsa-Pro is an MRI-guided, incision-free therapy used to treat prostate cancer and benign prostatic hyperplasia, or enlarged prostate.

Shares of Profound Medical were down about 3% in recent Tuesday trading.

Price: 7.54, Change: -0.23, Percent Change: -2.96

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601190768?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601190768","market":"fut","top_or_hot":-1,"title":"Profound Medical Says Johns Hopkins Treats First Patient With Tulsa-Pro Prostate Cancer Therapy","media":"MT Newswires Live","content":"<html><body><p> Profound Medical (PROF) said Tuesday that Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the company's Tulsa-Pro system.</p><p>Tulsa-Pro is an MRI-guided, incision-free therapy used to treat prostate cancer and benign prostatic hyperplasia, or enlarged prostate.</p><p>Shares of Profound Medical were down about 3% in recent Tuesday trading.</p><p>Price: 7.54, Change: -0.23, Percent Change: -2.96</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Profound Medical Says Johns Hopkins Treats First Patient With Tulsa-Pro Prostate Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProfound Medical Says Johns Hopkins Treats First Patient With Tulsa-Pro Prostate Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-07 00:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Profound Medical (PROF) said Tuesday that Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the company's Tulsa-Pro system.</p><p>Tulsa-Pro is an MRI-guided, incision-free therapy used to treat prostate cancer and benign prostatic hyperplasia, or enlarged prostate.</p><p>Shares of Profound Medical were down about 3% in recent Tuesday trading.</p><p>Price: 7.54, Change: -0.23, Percent Change: -2.96</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2601190768","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601190768","pubTimestamp":1767717055,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Profound Medical  said Tuesday that Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the company's Tulsa-Pro system.Tulsa-Pro is an MRI-guided, incision-free therapy used to treat prostate cancer and benign prostatic hyperplasia, or enlarged prostate.Shares of Profound Medical were down about 3% in recent Tuesday trading.Price: 7.54, Change: -0.23, Percent Change: -2.96","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","PROF":"Profound Medical Corp."},"translate_title":"Profound Medical表示约翰·霍普金斯大学用Tulsa-Pro前列腺癌疗法治疗了首例患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PROF":1},"content_text":"Profound Medical (PROF) said Tuesday that Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the company's Tulsa-Pro system.Tulsa-Pro is an MRI-guided, incision-free therapy used to treat prostate cancer and benign prostatic hyperplasia, or enlarged prostate.Shares of Profound Medical were down about 3% in recent Tuesday trading.Price: 7.54, Change: -0.23, Percent Change: -2.96","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601190768","isCrawlerRequest":true}